SCHEMBL1695482

SCHEMBL1695482

CCC(=O)OC1=CCCCCC1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 2/20 0.40
HIF1A Q16665 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
RECQL P46063 1/20 0.40
KMT2A Q03164 1/20 0.40
GSTP1 P09211 1/20 0.38
RAB9A P51151 2/20 0.36
ALDH1A1 P00352 1/20 0.36
ALOX15 P16050 1/20 0.35
CTSK P43235 1/20 0.35
HDAC4 P56524 1/20 0.34
HDAC2 Q92769 1/20 0.34
HDAC8 Q9BY41 1/20 0.34
HDAC6 Q9UBN7 1/20 0.34
ELANE P08246 1/20 0.33
ACHE P22303 1/20 0.32
KDM4E B2RXH2 1/20 0.32
NPC1 O15118 1/20 0.31
FGFR1 P11362 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1695485 1.00 ESR1 (0.40) ESR1HIF1ASMN1; SMN2RECQLKMT2A
SCHEMBL7622874 1.00 ESR1 (0.40) ESR1HIF1ASMN1; SMN2RECQLKMT2A
SCHEMBL11615936 1.00 ESR1 (0.40) ESR1HIF1ASMN1; SMN2RECQLKMT2A
SCHEMBL1695487 1.00 ESR1 (0.40) ESR1HIF1ASMN1; SMN2RECQLKMT2A
SCHEMBL7622870 1.00 ESR1 (0.40) ESR1HIF1ASMN1; SMN2RECQLKMT2A
SCHEMBL1695435 0.98 ESR1 (0.41) ESR1HIF1ASMN1; SMN2RECQLKMT2A
SCHEMBL1695501 0.93 HIF1A (0.42) ESR1HIF1ASMN1; SMN2RECQLKMT2A
SCHEMBL1695769 0.86 ALOX15 (0.38) ESR1SMN1; SMN2KMT2AGSTP1RAB9A
SCHEMBL1695767 0.86 ALOX15 (0.38) ESR1SMN1; SMN2KMT2AGSTP1RAB9A
SCHEMBL1695483 0.86 ALOX15 (0.38) ESR1SMN1; SMN2KMT2AGSTP1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2582453-B1 TRANSESTERIFICATION PROCESS USING MIXED SALT ACETYLACETONATES CATALYSTS ECOSYNTH NV (BE) 2016-12-28 EP disclosed
CN-103140287-B Use the ester exchange method of salt-mixture acetylacetonate catalyst 埃科辛斯私人有限公司 2016-08-03 CN disclosed
US-8865931-B2 Transesterification process using mixed salt acetylacetonates catalysts ECOSYNTH BVBA (BE) 2014-10-21 US disclosed
CN-103140287-A Transesterification process using mixed salt acetylacetonates catalysts ECOSYNTH BVBA 2013-06-05 CN disclosed
EP-2582453-A2 TRANSESTERIFICATION PROCESS USING MIXED SALT ACETYLACETONATES CATALYSTS Ecosynth BVBA (BE) 2013-04-24 EP disclosed
US-20130090492-A1 TRANSESTERIFICATION PROCESS USING MIXED SALT ACETYLACETONATES CATALYSTS ECOSYNTH BVBA (BE) 2013-04-11 US disclosed
WO-2011157645-A2 TRANSESTERIFICATION PROCESS USING MIXED SALT ACETYLACETONATES CATALYSTS ECOSYNTH BVBA (BE) 2011-12-22 WO disclosed
US-4112235-A Transesterification of carboxylic acids UOP INC. (US) 1978-09-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130090492-A1 TRANSESTERIFICATION PROCESS USING MIXED SALT ACETYLACETONATES CATALYSTS ACACA, ACACB, ACSL6 ESR1 1323/4885HIF1A 3621/4885SMN1; SMN2 3991/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.